1357 related articles for article (PubMed ID: 26081345)
1. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis.
van Nieuwenhuijze AE; van de Loo FA; Walgreen B; Bennink M; Helsen M; van den Bersselaar L; Wicks IP; van den Berg WB; Koenders MI
Arthritis Res Ther; 2015 Jun; 17(1):163. PubMed ID: 26081345
[TBL] [Abstract][Full Text] [Related]
2. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
Lubberts E; Koenders MI; Oppers-Walgreen B; van den Bersselaar L; Coenen-de Roo CJ; Joosten LA; van den Berg WB
Arthritis Rheum; 2004 Feb; 50(2):650-9. PubMed ID: 14872510
[TBL] [Abstract][Full Text] [Related]
3. Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model.
Plater-Zyberk C; Joosten LA; Helsen MM; Koenders MI; Baeuerle PA; van den Berg WB
Ann Rheum Dis; 2009 May; 68(5):721-8. PubMed ID: 18495731
[TBL] [Abstract][Full Text] [Related]
4. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease.
Cook AD; Braine EL; Campbell IK; Rich MJ; Hamilton JA
Arthritis Res; 2001; 3(5):293-8. PubMed ID: 11549370
[TBL] [Abstract][Full Text] [Related]
5. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis.
Koenders MI; Marijnissen RJ; Devesa I; Lubberts E; Joosten LA; Roth J; van Lent PL; van de Loo FA; van den Berg WB
Arthritis Rheum; 2011 Aug; 63(8):2329-39. PubMed ID: 21520013
[TBL] [Abstract][Full Text] [Related]
7. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1.
Koenders MI; Lubberts E; Oppers-Walgreen B; van den Bersselaar L; Helsen MM; Di Padova FE; Boots AM; Gram H; Joosten LA; van den Berg WB
Am J Pathol; 2005 Jul; 167(1):141-9. PubMed ID: 15972960
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 17 regulates SHP-2 and IL-17RA/STAT-3 dependent Cyr61, IL-23 and GM-CSF expression and RANKL mediated osteoclastogenesis by fibroblast-like synoviocytes in rheumatoid arthritis.
Ganesan R; Rasool M
Mol Immunol; 2017 Nov; 91():134-144. PubMed ID: 28898718
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation.
Cook AD; Louis C; Robinson MJ; Saleh R; Sleeman MA; Hamilton JA
Arthritis Res Ther; 2016 Dec; 18(1):287. PubMed ID: 27908288
[TBL] [Abstract][Full Text] [Related]
10. IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro.
Boutet MA; Najm A; Bart G; Brion R; Touchais S; Trichet V; Layrolle P; Gabay C; Palmer G; Blanchard F; Le Goff B
Ann Rheum Dis; 2017 Jul; 76(7):1304-1312. PubMed ID: 28288964
[TBL] [Abstract][Full Text] [Related]
11. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis.
Koenders MI; Kolls JK; Oppers-Walgreen B; van den Bersselaar L; Joosten LA; Schurr JR; Schwarzenberger P; van den Berg WB; Lubberts E
Arthritis Rheum; 2005 Oct; 52(10):3239-47. PubMed ID: 16200598
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model.
Zhang Y; Ren G; Guo M; Ye X; Zhao J; Xu L; Qi J; Kan F; Liu M; Li D
Int Immunopharmacol; 2013 Feb; 15(2):199-205. PubMed ID: 23280345
[TBL] [Abstract][Full Text] [Related]
14. Dependence of interleukin-1-induced arthritis on granulocyte-macrophage colony-stimulating factor.
Yang YH; Hamilton JA
Arthritis Rheum; 2001 Jan; 44(1):111-9. PubMed ID: 11212148
[TBL] [Abstract][Full Text] [Related]
15. Chimeric anti-IL-17 full-length monoclonal antibody is a novel potential candidate for the treatment of rheumatoid arthritis.
Bai F; Tian H; Niu Z; Liu M; Ren G; Yu Y; Sun T; Li S; Li D
Int J Mol Med; 2014 Mar; 33(3):711-21. PubMed ID: 24378614
[TBL] [Abstract][Full Text] [Related]
16. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction.
Lubberts E; Joosten LA; van Den Bersselaar L; Helsen MM; Bakker AC; van Meurs JB; Graham FL; Richards CD; van Den Berg WB
J Immunol; 1999 Oct; 163(8):4546-56. PubMed ID: 10510398
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis.
Chao CC; Chen SJ; Adamopoulos IE; Davis N; Hong K; Vu A; Kwan S; Fayadat-Dilman L; Asio A; Bowman EP
Autoimmunity; 2011 May; 44(3):243-52. PubMed ID: 20925596
[TBL] [Abstract][Full Text] [Related]
18. Induction of cartilage damage by overexpression of T cell interleukin-17A in experimental arthritis in mice deficient in interleukin-1.
Koenders MI; Lubberts E; Oppers-Walgreen B; van den Bersselaar L; Helsen MM; Kolls JK; Joosten LA; van den Berg WB
Arthritis Rheum; 2005 Mar; 52(3):975-83. PubMed ID: 15751058
[TBL] [Abstract][Full Text] [Related]
19. IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model.
Ohtsuji M; Lin Q; Nishikawa K; Ohtsuji N; Okazaki H; Tsurui H; Amano H; Shirai T; Nishimoto N; Nishimura H; Hirose S
Mod Rheumatol; 2015 Mar; 25(2):270-7. PubMed ID: 25159156
[TBL] [Abstract][Full Text] [Related]
20. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.
Joosten LA; Helsen MM; Saxne T; van De Loo FA; Heinegard D; van Den Berg WB
J Immunol; 1999 Nov; 163(9):5049-55. PubMed ID: 10528210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
